Premarket Movers Nov 9, 2026: Why CKX, GFR, EDSA Are Up

CKX — CKX LANDS, INC. (+62.2%)

CKX Lands is up 62.2% in premarket trading, at $17.70, on 2,858,801 shares. Its 20-day average volume is just 1,873 shares, so this is an enormous surge in activity for a tiny company with a $21.5M market cap. Premarket volume is lighter than regular hours, which makes the prints even more striking.

The likely catalyst is a $1 billion cash equity investment led by Brad Jacobs, announced November 9 and described in an 8-K filed the same day. Jacobs Private Equity II would contribute $900 million and co-investors led by HRTG Partners the other $100 million. That would give the fund a majority stake and make Jacobs chairman and CEO at closing. Closing is expected in early 2027 and needs stockholder approval.

Before closing, CKX plans a $20.8 million dividend ($10.1312 per share) and a 4.1744380:1 reverse split as part of a holding-company reorganization. Neither has taken effect yet. The 8-K also flags possible dilution from warrants and preferred stock. The deal is not final, and the per-share figures could change how the stock trades.

On the prior-day chart, CKX carried no setup signal: RSI 47, ADX 7 (no real trend), a mixed moving-average stack, and a price 16.1% below its 52-week high. Its free float is 62.2% and short volume is 60%. A thin float plus this volume can make prices swing wildly.

GFR — Greenfire Resources Ltd. (+38.3%)

Greenfire is up 38.3% in premarket trading, at $7.76, on 1,666,287 shares. That is already above its 20-day average of 1,237,130. Market cap is $703.5M.

The headlines point to an acquisition: Strathcona Resources agreed to buy Greenfire in a cash-and-stock deal reported at C$2.7 billion to C$2.9 billion (up to about $2.05 billion in one report). Benzinga asked why the stock was "skyrocketing Monday." We have no further deal terms beyond those headlines.

Takeover targets often trade near the deal value rather than continuing to climb, and the deal still has to close. The prior-day chart showed no setup: RSI 35, ADX 25, a mixed MA stack, and a price 21.6% below its 52-week high. Free float is 28.9% (low float means few shares available to trade) and short volume is 43%. Its smart-money score is 25/100, with a largest disclosed stake of 5.5%.

EDSA — Edesa Biotech, Inc. (+36.1%)

Edesa Biotech is up 36.1% premarket, at $2.98, on 20,864,289 shares versus a 20-day average of 46,001. Market cap is only $21.1M.

The likely catalyst is a licensing deal. Edesa signed an agreement on November 8 giving Kyorin exclusive rights to develop and sell paridiprubart, its anti-TLR4 antibody, in Japan for ARDS, announced November 9. One headline puts the deal at up to $146 million, but upfront and milestone amounts could not be confirmed here, so check the press release or 8-K. Edesa also told H.C. Wainwright it would end their at-the-market offering agreement effective November 16, with no termination penalties.

The prior-day setup was weak: RSI 28, ADX 32 with a bearish MA stack, and a price 89.2% below its 52-week high. Free float is 51.1% and short volume 54%. Smart-money score is 36/100, with a largest disclosed stake of 16.3%. Micro-cap biotechs like this can reverse sharply.

NCPL — Netcapital Inc. (+20.2%)

Netcapital is up 20.2% premarket, at $1.52, on 1,633,184 shares, well below its 20-day average of 15,969,605. Market cap is $9.9M. Light volume means the move can be fragile.

Headlines say Netcapital received a Nasdaq extension to regain compliance with its periodic filing requirement, and an 8-K was filed November 9. That is the most likely driver, though no deeper explanation is available. The company has a troubled backdrop: an October 14 8-K on delisting, an October 20 8-K flagged as dilution, and a securities fraud lawsuit notice from the Rosen Law Firm.

The prior-day chart showed a bullish MA stack, RSI 47, ADX 32, and a price 52.4% below its 52-week high. Conviction is 28/100 (grade D). Free float is 46.9% and short volume 42%. Smart-money score is 29/100.

VIR — Vir Biotechnology, Inc. (+22.9%)

Vir is up 22.9% premarket, at $15.00, on 432,487 shares versus a 20-day average of 1,672,485. Market cap is $2.1B, much larger than the others here.

The most likely catalyst is positive Phase 3 data for its hepatitis delta drug, released before the open. Per Investing.com, the ECLIPSE 1 trial of elebsiran and tobevibart met all primary and key secondary endpoints, with 44% of patients on the combination showing undetectable virus and normalized ALT at Week 48. These details rest on press coverage. Buyout chatter on social media is unconfirmed.

The prior-day chart was constructive: RSI 60, ADX 18, a bullish MA stack, and the stock at a 52-week high. Relative strength rating is 98. Conviction is 10/100 (grade D). Free float is 68.7% and short volume 64%. Largest disclosed stake is 12.4%.

The bottom line

These are the most volatile stocks in the market, and several are micro-caps with thin floats. Premarket gains often fade once the regular session opens, and deals and trial results carry real risk. Chasing extended gainers is high-risk, and patterns and squeezes fail often. Manage risk and do your own research. This is educational, not financial advice.

StockSetups scans the full US universe after every close and every premarket morning to surface movers like these. For more, see Premarket Movers Nov 6, 2026.